Working with small molecules: Rules-of-Thumb of "drug likeness"

Methods in Molecular Biology

Volumn 803, Issue , 2012, Pages 297-307

  Zhang, Ming Qiang ^a  

^a MERCK RESEARCH LABORATORIES   (United States)

Author keywords

Chemotype; Drug properties; Drug likeness

Indexed keywords

DRUG; LIGAND;

ARTICLE; CHEMISTRY; DOSE RESPONSE; HUMAN; MOLECULAR LIBRARY; PERMEABILITY; SOLUBILITY;

DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; LIGANDS; PERMEABILITY; PHARMACEUTICAL PREPARATIONS; SMALL MOLECULE LIBRARIES; SOLUBILITY;

EID: 82355188165     PISSN: 10643745     EISSN: None     Source Type: Book Series    
DOI: 10.1007/978-1-61779-364-6_20     Document Type: Article

References (25)

1. Takaoka, Y., Endo, Y., Yamanobe, S., Kakinuma, H., Okubo, T., Shimazaki, Y., Ota,T., Sumiya, S., and Yoshikawa, K. (2003) Development of a method for evaluating drug-likeness and ease of synthesis using a data set in which compounds are assigned scores based on chemists' intuition. J. Chem. Inf. Comput. Sci. 43, 1269-1275.
2. Leeson, P.D., and Springthorpe, B. (2007) The influence of drug-like concepts on decisionmaking in medicinal chemistry. Nat. Rev. Drg Disc. 6, 881-890. (Pubitemid 350042396)
3. Young, D.C. Computational Drug Design: A Guide for Computational and Medicinal Chemists, Wiley-Interscience (February 12, 2009) ISBN-10: 047012685X; Tudor I. Oprea (Editor). Chemoinformatics in Drug Discovery. Wiley-VCH (May 6, 2005) ISBN-10: 3527307532 and other volumes in the book series of Methods and Principles in Medicinal Chemistry, Mannhold R., Kubinyi H., and Folkers G (Eds).
4. Lipkus, A.H., Yuan, Q., Lucas, K.A., Funk, S.A., Bartelt III, W. F., Schenck, R. J., and Trippe, A.J. (2008) Structural diversity of organic chemistry. A scaffold analysis of the CAS registry. J. Org. Chem. 73, 4443-4451. (Pubitemid 351842458)
5. Bemis, G.W., and Murcko, M.A. (1996) The properties of known drugs. 1. Molecular frameworks. J. Med. Chem 39, 2887-2893. (Pubitemid 26251026)
6. Duarte, C.D., Barreiro, E.J., and Fraga, C.A. (2007) Privileged structures: a useful concept for the rational design of new lead drug candidates. Mini Rev. Med. Chem. 7, 1108-1119. (Pubitemid 350200217)
7. Abad-Zapatero, C., and Metz, J.T. (2005) Ligand efficiency indices as guideposts for drug discovery. Drug Disc Today 10, 464-469.
8. Bembenek, S.D., Tounge, B.A., and Reynolds, C.H. (2009) Ligand efficiency and fragmentbased drug discovery. Drug Disc. Today 14, 278-283.
9. Nissink, J.W.M. (2009) Simple size-independent measure of ligand efficiency. J. Chem. Inf. Model 49, 1617-1622.
10. Olsson, T.S.G., Williams, M.A., Pitt, W.R., and Ladbury, J.E. (2008) The thermodynamics of protein-ligand interaction and salvation: insights for ligand design. J. Mol. Biol. 384, 1002-1017.
11. Freire, E. (2008) Do enthalpy and entropy distinguish first-in-class from best-in-class? Drug Disc. Today 13, 869-874.
12. Copeland, R.A., Pompliano, D.L, and Meek, T.D. (2006) Drug-target residence time and its implications for lead optimization. Nat. Rev Drug Disc. 5, 730-739. (Pubitemid 44323700)
13. LoRusso, P.M., and Eder, J.P. (2008) Therapeutic potential of novel selective-spectrum kinase inhibitors in oncology. Expert Opin. Invest. Drugs 17, 1013-1028.
14. Lipinski, C.A., Lombardo, F., Dominy, B.W., and Feeney, P.J. (1997) Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv. Drug Deliv. Rev. 23, 3-25. (Pubitemid 27046991)
15. van de Waterbeemd, H., Smith D.A., Beaumont K., and Walker D.K. (2001) Property-based design: Optimization of drug absorption and pharmacokinetics. J. Med. Chem. 44, 1313-1333. (Pubitemid 32852106)
16. Pajouhesh, H., and Lenz, G.R. (2005) Medicinal chemical properties of successful central nervous system drugs. NeuroRx 2, 541-553. (Pubitemid 41393264)
17. Waring, M.J. (2009) Defining optimum lipophilicity and molecular weight ranges for drug candidates - Molecular weight dependent lower logD limits based on permeability. Bioorg. Med. Chem. Lett. 19, 2844-2851.
18. Ritchie, T.J., and Macdonald, S.J.F. (2009) The impact of aromatic ring count on compound developability - Are too many aromatic rings a liability in drug design? Drug Discovery Today 14, 1011-1020.
19. Kerns, E.H., and Di, L. (2008) Drug-like properties: Concepts, structure, design and methods, from ADME to toxicity optimization. ISBN 978-0-1236-9520-8, Academic Press, Burlington, MA 01803, USA, pp64.
20. Lipinski, C.A. (2000) Drug-like properties and the cause of poor solubility and poor permeability. J. Pharmacol. Toxicol. Methods 44, 235-249. (Pubitemid 32239479)
21. Smith, D.A., van de Waterbeemd, H., and Walker, D.K. (2001) Pharmacokinetics and metabolism in drug design. ISBN 3-527-30197-6, Wiley-VCH Verlag GmbH, Weinheim, Germany, pp 99-122.
22. Williams, D.P., and Park B.K. (2003) Idiosyncratic toxicity: The role of toxicophores and bioactivation. Drug Discovery Today 8, 1044-1050 (Pubitemid 38018811)
23. Waring, M.J. (2010) Lipophilicity in drug discovery. Expert Opin. Drug Discov. 5, 235-248.
24. Ploemen, J.P., Kelder, J., Hafmans, T., van de Sandt, H., van Burgsteden J.A., Saleminki P.J., and van Esch E. (2004) Use of physicochemical calculation of pKa and CLogP to predict phospholipidosis-inducing potential: a case study with structurally related piperazines. Exp Toxicol Pathol. 55, 347-55. (Pubitemid 38425469)
25. Wiseman, T., Williston, S., Brandts, J.F., and Lin, L.N. (1989) Rapid measurement of binding constants and heats of binding using a new titration calorimeter. Anal Biochem. 179, 131-137. (Pubitemid 19149635)